Name: Inhibikase Therapeutics, Inc. (IKT) Balance Sheet
Creator: FinSpry

Inhibikase Therapeutics Balance Sheet Analysis

Assets, liabilities, and stockholders equity in millions USD

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Inhibikase Therapeutics, Inc. (IKT) - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Current Assets
Cash and Cash Equivalents	56.49	13.25	7.19	40.75	13.95
Short-Term Investments	41.05	4.09	15.86	0.00	0.00
Cash & Short-Term Investments	97.54	13.25	23.05	40.75	13.95
Accounts Receivable	0.00	0.00	0.04	0.11	0.00
Inventory	0.00	0.00	0.00	0.00	0.00
Other Current Assets	0.83	0.74	0.16	1.50	0.05
Total Current Assets	98.45	14.21	24.37	42.47	14.78
Non-Current Assets
Property, Plant & Equipment (Net)	0.15	0.30	0.57	0.00	0.00
Other Non-Current Assets	0.00	0.00	0.00	0.00	0.00
Total Non-Current Assets	0.15	0.30	0.57	0.00	0.00
Total Assets	98.60	14.51	24.94	42.47	14.78
Current Liabilities
Accounts Payable	0.94	2.91	1.15	1.09	1.72
Short-Term Debt	0.11	0.00	0.00	0.25	0.00
Current Portion of Long-Term Debt	0.00	0.00	0.00	0.25	0.00
Accrued Liabilities	1.68	2.26	1.94	2.72	0.63
Deferred Revenue	0.00	0.00	0.00	0.00	2.33
Other Current Liabilities	2.68	0.00	0.00	0.00	0.00
Total Current Liabilities	3.73	3.44	3.70	4.05	4.72
Non-Current Liabilities
Long-Term Debt	0.00	0.09	0.21	0.00	0.28
Other Non-Current Liabilities	0.00	0.38	0.00	0.00	0.00
Total Non-Current Liabilities	0.00	0.38	0.21	0.00	0.00
Total Liabilities	3.73	3.53	3.90	4.05	5.00
Stockholders' Equity
Common Stock	0.07	0.01	0.00	0.03	0.01
Retained Earnings	-94.42	-66.90	-47.87	-29.82	-15.03
Accumulated Other Comprehensive Income	-0.04	0.00	0.10	0.00	0.00
Additional Paid-in Capital	189.25	77.87	68.80	68.21	0.00
Shares Outstanding	69.36	6.19	4.20	4.19	0.00
Total Stockholders' Equity	94.87	10.98	21.04	38.42	9.78
Total Liabilities & Equity	98.60	14.51	24.94	42.47	0.00